Daxeshkumar P Patel

Dr. Daxeshkumar P Patel

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in International Journal of Cancer
Verified
Journal Article
Open access
DPDaxeshkumar P Patel
Daxeshkumar P Patel
CLChristopher A. Loffredo
Christopher A. Loffredo
BPBenjarath Pupacdi
Benjarath Pupacdi
SRSiritida Rabibhadana
Siritida Rabibhadana
PNPanida Navasumrit
Panida Navasumrit
TCthe TIGER‐LC Consortium
the TIGER‐LC Consortium
Glyphosate [N‐(phosphonomethyl) glycine], a systemic herbicide, is used globally (825 million kg/year) in 750+ formulations. The International Agency for Research on Cancer classified glyphosate is a probable human carcinogen (Group 2A), but epidemiological studies have been lacking for its association with liver cancer and chronic liver disease. We analyzed urine specimens from 591 patients with newly diagnosed liver cancer, chronic liver disease (CLD), and healthy individuals from five different medical centers between 2011 to 2016 in Thailand. Gas chromatography electrospray ionization mass spectrometry (GC‐ESI/MS) was used to quantify glyphosate and its metabolites, aminomethylphosphonic acid (AMPA) and phosphoric acid (PPA) to study their levels in urine of hepatocellular carcinoma (HCC) and CLD patients in comparison to matched healthy individuals. Significantly higher levels of glyphosate were found in CLD patients compared to HCC cases and hospital controls, while significantly elevated levels of both AMPA and PPA were observed in HCC and CLD patients compared to hospital controls. Glyphosate and its metabolites were also detected at low to moderately high levels in convenience samples of food products and drinking water. These results raise concerns about the potential role of glyphosate in chronic liver disease and liver cancer risk.

5 June 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Purpose: Nonsmokers account for 10% to 13% of all lung cancer cases in the United States. Etiology is attributed to multiple risk factors including exposure to secondhand smoking, asbestos, environmental pollution, and radon, but these exposures are not within the current eligibility criteria for early lung cancer screening by low-dose CT (LDCT). Experimental Design: Urine samples were collected from two independent cohorts comprising 846 participants (exploratory cohort) and 505 participants (validation cohort). The cancer urinary biomarkers, creatine riboside (CR) and N-acetylneuraminic acid (NANA), were analyzed and quantified using liquid chromatography–mass spectrometry to determine if nonsmoker cases can be distinguished from sex and age-matched controls in comparison with tobacco smoker cases and controls, potentially leading to more precise eligibility criteria for LDCT screening. Results: Urinary levels of CR and NANA were significantly higher and comparable in nonsmokers and tobacco smoker cases than population controls in both cohorts. Receiver operating characteristic analysis for combined CR and NANA levels in nonsmokers of the exploratory cohort resulted in better predictive performance with the AUC of 0.94, whereas the validation cohort nonsmokers had an AUC of 0.80. Kaplan–Meier survival curves showed that high levels of CR and NANA were associated with increased cancer-specific death in nonsmokers as well as tobacco smoker cases in both cohorts. Conclusions: Measuring CR and NANA in urine liquid biopsies could identify nonsmokers at high risk for lung cancer as candidates for LDCT screening and warrant prospective studies of these biomarkers.

9 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
TPTanvi Somabhai Patel
Tanvi Somabhai Patel
DPDaxeshkumar P Patel
Daxeshkumar P Patel
MSMallika Sanyal
Mallika Sanyal
PSPranav S. Shrivastav
Pranav S. Shrivastav
Purpose: In the present work, we examined the outcomes and accuracy of the Support vector machine (SVM) and the Naive Bayes algorithms on a dataset, to predict whether the patient has heart disease or not, and the patient’s survival prediction status. Method: The machine learning procedures were developed using the clinically validated datasets with sixteen attributes from the University of California, Irvine’s Centre for Machine Learning, and Intelligent Systems. Confusion matrix was used to visualise the accuracy, recall, precision, and error of the models. Statistical analysis was done to prove the model accuracy using the receiver operating characteristic (ROC) curve and area under the curve (AUC). Results: The proposed method of heart disease prediction using Naïve Bayes had 87 % accuracy. The accuracy for heart survivability models using SVM and Naïve Bayes were 88 % and 93 %. The model efficiency for heart survivability using ROC curve with AUC 0.93 for Naïve Bayes and AUC 0.91 for SVM. Conclusion: Such prediction systems can help the medical sector to save energy, cost, and time by providing more efficient techniques to forecast decisions with high accuracy. This study will enable the statisticians and researchers to select more efficient and accurate machine learning algorithms to achieve better prediction of the “cardiovascular disease”.

5 September 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
Xiaoxin WangXiaoxin Wang
Xiaoxin Wang
Komuraiah MyakalaKomuraiah Myakala
Komuraiah Myakala
ALAndrew E. Libby
Andrew E. Libby
JPJulia Panov
Julia Panov
SRSuman Ranjit
Suman Ranjit
PSPinaki Sarder
Pinaki Sarder
Background: A gradual decline in renal function occurs even in healthy aging individuals. In addition to aging per se , concurrent metabolic syndrome and hypertension, which are common in the aging population, can induce mitochondrial dysfunction and inflammation, which collectively contribute to age-related kidney dysfunction and disease. Here we studied the role of the nuclear hormone receptors, the estrogen-related receptors (ERRs) in regulation of age-related mitochondrial dysfunction and inflammation. ERRs were decreased in aging human and mouse kidneys and were preserved in aging mice with lifelong caloric restriction (CR). Methods: A pan-ERR agonist was used to treat 21-month-old mice for 8-weeks. In addition, 21-month-old mice were treated with a STING inhibitor for 3 weeks. Results: Remarkably, only an 8-week treatment with a pan-ERR agonist reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines, including the cGAS-STING and STAT3 signaling pathways. A 3-week treatment of 21-month-old mice with a STING inhibitor reversed the increases in inflammatory cytokines and the senescence marker p21 but also unexpectedly reversed the age-related decreases in PGC-1α, ERRα, mitochondrial complexes and MCAD expression. Conclusions: Our studies identified ERRs as important modulators of age-related mitochondrial dysfunction and inflammation. These findings highlight novel druggable pathways that can be further evaluated to prevent progression of age-related kidney disease. Significance Statement: There is an increasing need for prevention and treatment strategies for age-related kidney disease. The hallmarks of aging kidneys are decreased mitochondrial function and increased inflammation. The expression of the nuclear hormone receptors estrogen-related receptors (ERRs) are decreased in aging human and mouse kidneys. This paper investigates the role of ERRs in the aging kidney. Treatment of aging mice with a pan-ERR agonist reversed the age-related increases in albuminuria and podocyte loss, mitochondrial dysfunction and inflammatory cytokines, including the cGAS-STING signaling pathways. Treatment of aging mice with a STING inhibitor decreased inflammation and increased mitochondrial gene expression. These findings identify ERRs as important modulators of age-related mitochondrial dysfunction and inflammation.

11 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
BBBurchelle Blackman
Burchelle Blackman
NRNatarajan Raju
Natarajan Raju
CMChandrasekhar Mushti
Chandrasekhar Mushti
KLKelly Lane
Kelly Lane
DPDaxeshkumar P Patel
Daxeshkumar P Patel
RSRolf E. Swenson
Rolf E. Swenson
An untargeted metabolomic study identified four potential lung cancer diagnostic biomarkers in human urine. One of the potential biomarkers was an unidentified feature possessing a m/z value of 561+. “561+” was isolated from human urine and tentatively identified as 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol glucuronide with unknown C24,25 stereochemistry using 1H NMR and mass spectrometry. In a prior report, the C24,25 stereochemistry of the aglycone, 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol, was found to be 24S,25R through GC analysis of the acetonide-TMS derivative. An authentic sample was prepared and found not to have the same stereochemistry as ”561+”. To identify the C24,25 stereochemistry, four C24,C25 diastereoisomeric alcohols of 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol were prepared from chiral amino acids. Using an LCMS method, the C24,C25 stereochemistry of the “561+” aglycone was determined to be 24R,25S. With the correct aglycone in hand, it was coupled with glucuronic acid to complete the first reported synthesis of 27-nor-5β-cholestane-3α,7α,12α,24R,25S pentol glucuronide. Deuterium labeled 27-nor-5β-cholestane-3α,7α,12α,24R,25S pentol was also synthesized for use as an internal standard for MS quantitation.

25 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LTLeila Toulabi
Leila Toulabi
JSJoshua K. Stone
Joshua K. Stone
MKMohammed Khan
Mohammed Khan
DPDaxeshkumar P Patel
Daxeshkumar P Patel
RHRaffit Hassan
Raffit Hassan
CHCurtis C. Harris
Curtis C. Harris
Background: Malignant mesothelioma is a rare and aggressive malignancy with limited treatment options and poor survival outcomes. Current biomarkers such as MESOMARK, fibulin-3, and osteopontin show diagnostic potential but remain hampered by inconsistent sensitivity and reproducibility. Urine-based metabolites may provide a simple, noninvasive alternative for prognosis and disease monitoring. Methods: We evaluated whether four urinary metabolites—creatine riboside, N-acetylneuraminic acid, cortisol sulfate, and cholestane pentol—previously associated with prognosis in lung and liver cancer, are prognostic in mesothelioma. Urinary metabolite concentrations were quantified in a clinically annotated cohort with survival follow-up. Associations with overall survival and a validated poor-prognostic gene expression signature were analyzed. Results: Elevated urinary concentrations of the four metabolites were significantly correlated with poor-prognostic gene expression profiles. Patient survival declined progressively with the number of elevated metabolites, with the poorest outcomes observed in individuals harboring three or more high metabolites. These associations were independent of clinical variables and consistent in sensitivity analyses, suggesting that metabolite elevations reflect aggressive tumor biology. Interpretation: Urinary metabolites represent promising prognostic biomarkers in mesothelioma. Their additive and dose-dependent relationship with survival highlights their potential clinical utility for risk stratification, patient monitoring, and trial design. Because urine collection is noninvasive and repeatable, these biomarkers could complement existing blood-based assays and provide an accessible tool for clinical practice. Larger, multi-institutional studies are warranted to validate their prognostic significance and enable translation into patient care.